EXHIBIT 4.4
WARRANT AGREEMENT
This Warrant Agreement (“Warrant Agreement”) is made as of [ ] [ ], 2022, by and between Bellevue Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company (the “Warrant Agent”).
WHEREAS, the Company is engaged in a public offering (the “Public Offering”) of 6,000,000 units (the “IPO Units”) of the Company (and up to 900,000 additional IPO Units if the underwriters’ over-allotment option is exercised in full), each IPO Unit consisting of one share of common stock, par value $0.0001 per share (the “Common Stock”) and one warrant (“Public Warrants”), each Public Warrant entitling its holder to purchase one share of Common Stock (the “Public Warrant Shares”) at an exercise price of $11.50 per whole share;
WHEREAS, simultaneous with the consummation of the Public Offering, the Company intends to sell up to 390,000 units (the “Placement Units”) of the Company on a private placement basis (the “Private Placement”), each Placement Unit consisting of one share of Common Stock and one warrant (the “Placement Warrants”), each Placement Warrant entitling its holder to purchase one share of Common Stock (the “Placement Warrant Shares”, and, together with the Public Warrant Shares, the “Warrant Shares”) at an exercise price of $11.50 per whole share;
WHEREAS, following consummation of the Public Offering and the Private Placement, the Company may issue additional warrants (“Post IPO Warrants” and collectively with the Public Warrants and Placement Warrants, the “Warrants”) in connection with, or following the consummation by the Company of, an initial business combination;
WHEREAS, the Company has filed with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-1, No. 333-[ ] (“Registration Statement”), for the registration, under the Securities Act of 1933, as amended (the “Act”) of, among other securities, the Public Warrants;
WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, exchange, redemption and exercise of the Warrants;
WHEREAS, the Company desires to provide for the form, terms and provisions of the Warrants, including the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights and immunities of the Company, the Warrant Agent and the holders of the Warrants; and
WHEREAS, all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf of the Warrant Agent, as provided herein, the legally valid and binding obligations of the Company, and to authorize the execution and delivery of this Warrant Agreement.